Donate

The Weizmann Institute brings together scientists from a variety of disciplines to tackle cancer head-on. In the fourth episode of Weizmann in Focus, CEO Dave Doneson highlights a recent headline-making breakthrough from the labs of Profs. Ido Amit and Amos Tanay. Working with hospitals across Israel, the scientists identified a very small number of malignant cells in what is considered a pre-malignant stage of multiple myeloma—the second-most common type of blood cancer. Their discovery holds the promise of earlier, more precise treatment.